WALTER NMN LING

Summary

Country: USA

Publications

  1. ncbi Diffusion of substance abuse treatment: will buprenorphine be a success?
    Walter Ling
    UCLA Integrated Substance Abuse Programs, Neuropsychiatric Institute and Hospital, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, California, USA
    J Psychoactive Drugs . 2004
  2. doi Bupropion hydrochloride versus placebo, in combination with cognitive behavioral therapy, for the treatment of cocaine abuse/dependence
    Steve Shoptaw
    S David Geffen School of Medicine at UCLA, Department of Family Medicine, 10880 Wilshire Boulevard, Suite 540, Los Angeles, CA 90095, USA
    J Addict Dis 27:13-23. 2008
  3. doi Buprenorphine implant for opioid addiction
    Walter Ling
    Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, 1640 S Sepulveda Blvd, Suite 120, Los Angeles, CA 90025 7535, USA
    Pain Manag 2:345-50. 2012
  4. pmc A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network
    Walter Ling
    David Geffen School of Medicine, NPI Integrated Substance Abuse Programs, University of California, Los Angeles, CA 90025, USA
    Addiction 100:1090-100. 2005
  5. ncbi Management of methamphetamine abuse and dependence
    Walter Ling
    Integrated Substance Abuse Programs, David Geffen School of Medicine at UCLA, University of California Los Angeles, 11075 Santa Monica Boulevard, Suite 200, Los Angeles, CA 90025, USA
    Curr Psychiatry Rep 8:345-54. 2006
  6. pmc Buprenorphine tapering schedule and illicit opioid use
    Walter Ling
    University of California, Los Angeles, CA 90025, USA
    Addiction 104:256-65. 2009
  7. pmc Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience
    Leslie Amass
    Friends Research Institute, Inc, 11075 Santa Monica Boulevard, Suite 200, Los Angeles, CA 90025, USA
    Am J Addict 13:S42-66. 2004
  8. ncbi Clinical treatment of opioid addiction and dependence
    Walter Ling
    Integrated Substance Abuse Programs, University of California Los Angeles, Los Angeles, CA, USA
    Methods Mol Med 84:285-95. 2003
  9. pmc Randomized, double-blind, placebo-controlled trial of modafinil for the treatment of methamphetamine dependence
    Keith G Heinzerling
    Department of Family Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    Drug Alcohol Depend 109:20-9. 2010
  10. pmc Provision of ancillary medications during buprenorphine detoxification does not improve treatment outcomes
    Maureen Hillhouse
    University of California, Los Angeles, Integrated Substance Abuse Programs, Los Angeles, CA 90025, USA
    J Addict Dis 29:23-9. 2010

Detail Information

Publications65

  1. ncbi Diffusion of substance abuse treatment: will buprenorphine be a success?
    Walter Ling
    UCLA Integrated Substance Abuse Programs, Neuropsychiatric Institute and Hospital, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, California, USA
    J Psychoactive Drugs . 2004
    ..Clinician attitude and the extent to which they embrace buprenorphine will play an important role in determining the future success of this medication...
  2. doi Bupropion hydrochloride versus placebo, in combination with cognitive behavioral therapy, for the treatment of cocaine abuse/dependence
    Steve Shoptaw
    S David Geffen School of Medicine at UCLA, Department of Family Medicine, 10880 Wilshire Boulevard, Suite 540, Los Angeles, CA 90095, USA
    J Addict Dis 27:13-23. 2008
    ..The failure to find an effect for bupropion relative to placebo, when combined with standard cognitive behavioral therapy, dampens enthusiasm for future development of bupropion as a cocaine pharmacotherapy...
  3. doi Buprenorphine implant for opioid addiction
    Walter Ling
    Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, 1640 S Sepulveda Blvd, Suite 120, Los Angeles, CA 90025 7535, USA
    Pain Manag 2:345-50. 2012
    ....
  4. pmc A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network
    Walter Ling
    David Geffen School of Medicine, NPI Integrated Substance Abuse Programs, University of California, Los Angeles, CA 90025, USA
    Addiction 100:1090-100. 2005
    ....
  5. ncbi Management of methamphetamine abuse and dependence
    Walter Ling
    Integrated Substance Abuse Programs, David Geffen School of Medicine at UCLA, University of California Los Angeles, 11075 Santa Monica Boulevard, Suite 200, Los Angeles, CA 90025, USA
    Curr Psychiatry Rep 8:345-54. 2006
    ..Clinicians and researchers must interact to efficiently address the problems of methamphetamine dependence, a major drug problem in the United States and the world...
  6. pmc Buprenorphine tapering schedule and illicit opioid use
    Walter Ling
    University of California, Los Angeles, CA 90025, USA
    Addiction 104:256-65. 2009
    ..To compare the effects of a short or long taper schedule after buprenorphine stabilization on participant outcomes as measured by opioid-free urine tests at the end of each taper period...
  7. pmc Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience
    Leslie Amass
    Friends Research Institute, Inc, 11075 Santa Monica Boulevard, Suite 200, Los Angeles, CA 90025, USA
    Am J Addict 13:S42-66. 2004
    ....
  8. ncbi Clinical treatment of opioid addiction and dependence
    Walter Ling
    Integrated Substance Abuse Programs, University of California Los Angeles, Los Angeles, CA, USA
    Methods Mol Med 84:285-95. 2003
  9. pmc Randomized, double-blind, placebo-controlled trial of modafinil for the treatment of methamphetamine dependence
    Keith G Heinzerling
    Department of Family Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    Drug Alcohol Depend 109:20-9. 2010
    ..To compare modafinil to placebo for reducing methamphetamine (MA) use, improving retention, and reducing depressive symptoms and MA cravings. Rates of adverse events and cigarette smoking with modafinil versus placebo were also compared...
  10. pmc Provision of ancillary medications during buprenorphine detoxification does not improve treatment outcomes
    Maureen Hillhouse
    University of California, Los Angeles, Integrated Substance Abuse Programs, Los Angeles, CA 90025, USA
    J Addict Dis 29:23-9. 2010
    ..004). Results also indicate that participants attended fewer days of treatment if they received anxiety, nausea, or diarrhea medication compared to no medication (all P values < .05)...
  11. ncbi Clinical efficacy of buprenorphine: comparisons to methadone and placebo
    Walter Ling
    Integrated Substance Abuse Programs, Department of Psychiatry and Biobehavioral Sciences, School of Medicine, University of California Los Angles, 11075 Santa Monica Boulevard, Suite 200, Los Angeles 90025, CA, USA
    Drug Alcohol Depend 70:S49-57. 2003
    ..Also reviewed are three placebo-controlled trials and a buprenorphine/methadone detoxification study. Overall, this series of studies did firmly establish the efficacy of buprenorphine alone and in comparison to methadone...
  12. pmc From research to the real world: buprenorphine in the decade of the Clinical Trials Network
    Walter Ling
    Pacific Region Node, University of California, Los Angeles, USA
    J Subst Abuse Treat 38:S53-60. 2010
    ..Furthermore, this article explores current issues and future challenges that may require additional CTN efforts...
  13. ncbi A comparison of contingency management and cognitive-behavioral approaches during methadone maintenance treatment for cocaine dependence
    Richard A Rawson
    University of California, Los Angeles, Integrated Substance Abuse Programs, 11075 Santa Monica Blvd, Suite 200, Los Angeles, CA 90025, USA
    Arch Gen Psychiatry 59:817-24. 2002
    ..This study compared 2 psychosocial approaches for the treatment of cocaine dependence: contingency management (CM) and cognitive-behavioral therapy (CBT)...
  14. ncbi A screening trial of amantadine as a medication for cocaine dependence
    Steve Shoptaw
    Friends Research Institute, Inc, 11075 Santa Monica Blvd, Suite 350, Los Angeles, CA 90025, USA
    Drug Alcohol Depend 66:217-24. 2002
    ..There were no significant differences in frequency or severity of reported adverse events by treatment condition. These results provide moderate support for further study of amantadine for the treatment of cocaine dependence...
  15. doi Buprenorphine implants for treatment of opioid dependence: a randomized controlled trial
    Walter Ling
    Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, USA
    JAMA 304:1576-83. 2010
    ..Limitations of existing pharmacological treatments for opioid dependence include low adherence, medication diversion, and emergence of withdrawal symptoms...
  16. ncbi Randomized placebo-controlled trial of baclofen for cocaine dependence: preliminary effects for individuals with chronic patterns of cocaine use
    Steven Shoptaw
    UCLA Integrated Substance Abuse Program, Los Angeles, Calif 90025, USA
    J Clin Psychiatry 64:1440-8. 2003
    ..This screening trial evaluated whether the GABAB agonist baclofen demonstrated sufficient clinical efficacy to recommend an adequately powered trial of the medication as a pharmacotherapy for cocaine dependence...
  17. pmc Gabapentin improves cold-pressor pain responses in methadone-maintained patients
    Peggy Compton
    School of Nursing, University of California, Los Angeles, CA 90095, United States
    Drug Alcohol Depend 109:213-9. 2010
    ..These results support that GPN, as prescribed for the treatment of neuropathic pain, is effective in decreasing OIH in patients who are abstinent and stable in methadone treatment...
  18. ncbi Randomized, placebo-controlled trial of sertraline and contingency management for the treatment of methamphetamine dependence
    Steven Shoptaw
    Center for Health Promotion and Disease Prevention, Department of Family Medicine, David Geffen School of Medicine at UCLA, 10880 Wilshire Blvd, Suite 1800, Los Angeles, CA 90024, USA
    Drug Alcohol Depend 85:12-8. 2006
    ..This project evaluated the efficacy of sertraline (50mg bid) and contingency management (CM) for the treatment of methamphetamine dependence...
  19. ncbi Randomized, placebo-controlled trial of baclofen and gabapentin for the treatment of methamphetamine dependence
    Keith G Heinzerling
    Integrated Substance Abuse Programs, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA 90024, USA
    Drug Alcohol Depend 85:177-84. 2006
    ..To conduct a 16-week, randomized, placebo-controlled, double-blind trial of two GABAergic medications, baclofen (20 mg tid) and gabapentin (800 mg tid), for the treatment of methamphetamine dependence...
  20. pmc Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence
    Steven Shoptaw
    Department of Family Medicine, David Geffen School of Medicine at UCLA, 10880 Wilshire Boulevard, Suite 540, Los Angeles, CA 90095, USA
    Drug Alcohol Depend 96:222-32. 2008
    ..A secondary objective compared bupropion to placebo for reducing cigarette smoking among MA dependent participants...
  21. ncbi Pharmacokinetics, bioavailability and opioid effects of liquid versus tablet buprenorphine
    Peggy Compton
    School of Nursing, University of California at Los Angeles, Factor Building 4 246, Box 956918, Los Angeles, CA 90095 6918, USA
    Drug Alcohol Depend 82:25-31. 2006
    ....
  22. ncbi Cerebral metabolic dysfunction and impaired vigilance in recently abstinent methamphetamine abusers
    Edythe D London
    Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90024 1759, USA
    Biol Psychiatry 58:770-8. 2005
    ..The links between cognitive impairment and these cerebral abnormalities are not established...
  23. ncbi A comparison of contingency management and cognitive-behavioral approaches for stimulant-dependent individuals
    Richard A Rawson
    UCLA Integrated Substance Abuse Programs, Los Angeles, CA 90025, USA
    Addiction 101:267-74. 2006
    ..The present study sought to directly compare the effectiveness of (CM) and (CBT) alone and in combination in reducing stimulant use...
  24. ncbi Smoking cessation in methadone maintenance
    Steve Shoptaw
    Friends Research Institute, Los Angeles, CA, UCLA, Department of Psychiatry, Los Angeles, CA 90025, USA
    Addiction 97:1317-28; discussion 1325. 2002
    ..To evaluate relapse prevention (relapse prevention) and contingency management (contingency management) for optimizing smoking cessation outcomes using nicotine replacement therapy for methadone-maintained tobacco smokers...
  25. ncbi Buprenorphine: blending practice and research
    Walter Ling
    Integrated Substance Abuse Programs, University of California, Los Angeles, 11075 Santa Monica Boulevard, Suite 200, Los Angeles, CA 90025, USA
    J Subst Abuse Treat 23:87-92. 2002
    ..However, successful implementation will require changes in the understanding and attitude of clinicians, policymakers, and society...
  26. ncbi Buprenorphine 101: treating opioid dependence with buprenorphine in an office-based setting
    Matthew Torrington
    University of California, Los Angeles, USA
    J Addict Dis 26:93-9. 2007
    ..Physicians may benefit from this information by using it to tailor comprehensive treatment and medical care plans for opioid-dependent patients taking buprenorphine...
  27. ncbi Differences in regional brain metabolism associated with marijuana abuse in methamphetamine abusers
    Bradley Voytek
    Department of Psychiatry, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90024, USA
    Synapse 57:113-5. 2005
  28. ncbi Why we do what we do-delivery of buprenorphine and the treatment of opioid addiction
    Walter Ling
    Integrated Substance Abuse Programs, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Addiction 102:1908-9. 2007
  29. ncbi Variation in neurophysiological function and evidence of quantitative electroencephalogram discordance: predicting cocaine-dependent treatment attrition
    Sandy Venneman
    Medication Development Unit, Research Service, and Psychiatry Service, West Los Angeles VA Medical Center, California, USA
    J Neuropsychiatry Clin Neurosci 18:208-16. 2006
    ..Failure to complete the trial was not explained by depression, craving, benzoylecgonine levels or quantitative electroencephalogram (QEEG) power; thus cordance may help identify attrition risk...
  30. ncbi Methamphetamine abstinence syndrome: preliminary findings
    Thomas F Newton
    Department of Psychiatry and Biobehavioral Sciences, UCLA School of Medicine, Los Angeles, CA, USA
    Am J Addict 13:248-55. 2004
    ..The abstinence syndrome associated with methamphetamine dependence varied considerably in intensity and duration but generally was mild and resolved quickly for most individuals...
  31. ncbi Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methamphetamine abusers
    Edythe D London
    Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, University of California Los Angeles, 760 Westwood Plaza, PO Box 175919, Los Angeles, CA 90024 1759, USA
    Arch Gen Psychiatry 61:73-84. 2004
    ..Mood disturbances in methamphetamine (MA) abusers likely influence drug use, but the neurobiological bases for these problems are poorly understood...
  32. ncbi Randomized controlled pilot trial of cabergoline, hydergine and levodopa/carbidopa: Los Angeles Cocaine Rapid Efficacy Screening Trial (CREST)
    Steven Shoptaw
    UCLA Integrated Substance Abuse Programs, Los Angeles, CA 90025, USA
    Addiction 100:78-90. 2005
    ..5 mg per week (n = 15); and placebo three times daily (n = 15) as potential pharmacotherapies for cocaine dependence...
  33. doi Lack of effect of chronic dextromethorphan on experimental pain tolerance in methadone-maintained patients
    Peggy A Compton
    Acute Care Section, School of Nursing, University of California at Los Angeles, Factor Building 4 246, Box 956918, Los Angeles, CA 90095 6918, USA
    Addict Biol 13:393-402. 2008
    ..These results support that chronic high-dose NMDA antagonism does not improve tolerance for pain in MM patients, although a gender effect on DEX response is suggested...
  34. ncbi Irritability following abstinence from cocaine predicts euphoric effects of cocaine administration
    Thomas F Newton
    Department of Psychiatry and Biobehavioral Sciences, Neuropsychiatric Institute, UCLA School of Medicine, Room A7 372, 760 Westwood Boulevard, Los Angeles, CA 90024, USA
    Addict Behav 28:817-21. 2003
    ..If these findings are replicated in a larger sample, then it may be necessary to reconsider the applicability of the opponent process model to cocaine addiction in humans...
  35. ncbi Quantitative EEG abnormalities in recently abstinent methamphetamine dependent individuals
    Thomas F Newton
    Department of Psychiatry and Biobehavioral Sciences, UCLA School of Medicine, Los Angeles, CA, USA
    Clin Neurophysiol 114:410-5. 2003
    ....
  36. ncbi The Clinical Opiate Withdrawal Scale (COWS)
    Donald R Wesson
    CNS Medications Development, Oakland, California, USA
    J Psychoactive Drugs 35:253-9. 2003
    ..PDF formatted versions of the COWS are also available from the websites of the American Society of Addiction Medicine, the California Society of Addiction Medicine, the UCLA Integrated Substance Abuse Programs, and AlcoholMD.com...
  37. ncbi Effect of oral ketorolac and gender on human cold pressor pain tolerance
    Peggy Compton
    School of Nursing, University of California at Los Angeles, Los Angeles, California, USA
    Clin Exp Pharmacol Physiol 30:759-63. 2003
    ....
  38. ncbi Dancing with strangers: will U.S. substance abuse practice and research organizations build mutually productive relationships?
    Richard A Rawson
    UCLA Integrated Substance Abuse Programs ISAP, 11075 Santa Monica Boulevard, No 200, Los Angeles, CA 90025, USA
    Addict Behav 27:941-9. 2002
    ..However, while the music has started and the partners seem willing, there are still many obstacles to a successful dance...
  39. ncbi Structural abnormalities in the brains of human subjects who use methamphetamine
    Paul M Thompson
    Laboratory of Neuroimaging, Brain Mapping Division, Department of Neurology, University of California Los Angeles School of Medicine, Los Angeles, California 90095 1769, USA
    J Neurosci 24:6028-36. 2004
    ..These brain substrates may help account for the symptoms of MA abuse, providing therapeutic targets for drug-induced brain injury...
  40. ncbi Will the methamphetamine problem go away?
    Richard A Rawson
    UCLA Integrated Substance Abuse Programs, UCLA Department of Psychiatry, USA
    J Addict Dis 21:5-19. 2002
    ..This article reviews the issues concerning the future of the methamphetamine problem in the US and provides some recommendations for setting priorities to address the problem...
  41. ncbi Association between quantitative EEG and neurocognition in methamphetamine-dependent volunteers
    Thomas F Newton
    Department of Psychiatry and Biobehavioral Sciences, Neuropsychiatric Institute, UCLA School of Medicine, Room A7 372, 760 Westwood Plaza, Los Angeles, CA 90024, USA
    Clin Neurophysiol 115:194-8. 2004
    ..Exposure to methamphetamine is associated with long-lasting reductions in markers for dopaminergic neurons in preclinical models and in humans. These changes may be associated with alterations in brain electrical activity and in cognition...
  42. ncbi Status of methamphetamine users 2-5 years after outpatient treatment
    Richard A Rawson
    Matrix Institute on Addictions, Los Angeles, CA 90025, USA
    J Addict Dis 21:107-19. 2002
    ..In general, the follow up status of the sample was much improved as compared to before treatment. However, headaches and depression were reported at a similar rate at follow up as had been reported at treatment admission...
  43. ncbi Participants receiving dehydroepiandrosterone during treatment for cocaine dependence show high rates of cocaine use in a placebo-controlled pilot study
    Steve Shoptaw
    Friends Research Institute, Los Angeles, CA, USA
    Exp Clin Psychopharmacol 12:126-35. 2004
    ..No differences were detected between conditions for cocaine craving or adverse experiences. High levels of medication compliance were documented. Results argue against using high doses of DHEA as a pharmacotherapy for cocaine dependence...
  44. ncbi The effect of relapse on cognition in abstinent methamphetamine abusers
    Sara L Simon
    UCLA Integrated Substance Abuse Programs, Los Angeles, CA, USA
    J Subst Abuse Treat 27:59-66. 2004
    ..Relapse to methamphetamine use may affect episodic memory differently than it affects the other cognitive functions measured...
  45. ncbi Bupropion for the treatment of methamphetamine dependence
    Ahmed M Elkashef
    Clinical Medical Branch, Division of Pharmacotherapies and Medical Consequences, National Institutes of Health, National Institute on Drug Abuse, Bethesda, MD, USA
    Neuropsychopharmacology 33:1162-70. 2008
    ....
  46. ncbi Opioid effects and opioid withdrawal during a 24 h dosing interval in patients maintained on buprenorphine
    Olga V Lopatko
    Department of Clinical and Experimental Pharmacology, University of Adelaide, Adelaide 5005, SA, Australia
    Drug Alcohol Depend 69:317-22. 2003
    ....
  47. ncbi A preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of methamphetamine dependence
    Bankole A Johnson
    Department of Psychiatry and Neurobehavioral Sciences, University of Virginia, Charlottesville, VA 22908 0623, USA
    Int J Neuropsychopharmacol 11:1-14. 2008
    ..These findings should be viewed in light of the possibility that a less intensive cognitive behavioural therapy regimen might have yielded more positive results in this initial phase II trial exploring for the efficacy of ondansetron...
  48. ncbi Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone
    Paul J Fudala
    Veterans Affairs VA Medical Center, University of Pennsylvania School of Medicine, Philadelphia, USA
    N Engl J Med 349:949-58. 2003
    ..Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone has been proposed, but its efficacy and safety have not been well studied...
  49. ncbi Methadone maintenance patients are cross-tolerant to the antinociceptive effects of very high plasma morphine concentrations
    Peter Athanasos
    Department of Clinical and Experimental Pharmacology, University of Adelaide, Adelaide, SA 5005, Australia
    Pain 120:267-75. 2006
    ..While even higher morphine doses may achieve some pain relief, this may be at the cost of unacceptable respiratory depression...
  50. ncbi Pharmacists' and technicians' perceptions and attitudes toward dispensing buprenorphine/ naloxone to patients with opioid dependence
    Dennis W Raisch
    Veterans Affairs Cooperative Studies Program, Clinical Research Pharmacy Coordinating Center, Albuquerque, NM 87106, USA
    J Am Pharm Assoc (2003) 45:23-32. 2005
    ..To assess the perceptions and attitudes of pharmacists and pharmacy technicians involved in an office-based opioid dependence treatment program using buprenorphine/naloxone...
  51. ncbi Opiate recidivism in a drug-treatment program: comparison of hair and urine data
    Bradley K Charles
    Center for Human Toxicology, University of Utah, Salt Lake City, Utah 84112, USA
    J Anal Toxicol 27:412-28. 2003
    ..Urine appeared to be a more sensitive indicator of changes in the pattern(s) of drug use during the course of clinical drug treatment...
  52. ncbi Medications development: successes and challenges
    Frank Vocci
    Division of Pharmacotherapies and Medical Consequences of Drug Abuse, National Institute on Drug Abuse, National Institutes of Health, 6001 Executive Boulevard, Ste 4123, MSC 9551, Bethesda, MD 20892, USA
    Pharmacol Ther 108:94-108. 2005
    ..Initial studies are underway. Both agonist and antagonist approaches will be evaluated. Additionally, medications will be tested in cannabis-dependent patients for the management of insomnia, withdrawal, and concurrent depression...
  53. ncbi If a US drug abuse epidemic fails to include a major east coast city, can it be called an epidemic?
    Richard A Rawson
    J Addict Dis 21:1-4. 2002
  54. ncbi Cognitive performance of current methamphetamine and cocaine abusers
    Sara L Simon
    UCLA Integrated Substance Abuse Programs ISAP, USA
    J Addict Dis 21:61-74. 2002
    ..When compared to their matched non-using control groups, both MA and COC abusers were impaired on cognitive measures, but the type and degree of impairments were somewhat different...
  55. ncbi A comparison of patterns of methamphetamine and cocaine use
    Sara L Simon
    Los Angeles Addiction Research Consortium, USA
    J Addict Dis 21:35-44. 2002
    ..The cocaine pattern of fewer days of use, evening use, and more frequent doses per day fits a picture of recreational use, whereas the all-day-most-days methamphetamine pattern does not...
  56. ncbi Cochrane systematic reviews: time for an introduction and appraisal
    Walter Ling
    Drug Alcohol Depend 73:217-8. 2004
  57. ncbi Cognitive deficits among methamphetamine users with attention deficit hyperactivity disorder symptomatology
    Tiffanie Sim
    Los Angeles Addiction Research Consortium, USA
    J Addict Dis 21:75-89. 2002
    ..The preliminary data suggests that executive function deficits and some of the symptoms associated with long-term MA use may be due to the fact that a large proportion of MA addicts had ADHD symptomatology as children...
  58. ncbi Naltrexone and dysphoria: fact or myth?
    Karen Miotto
    UCLA Department of Psychiatry and Biobehavioral Sciences, 90024, USA
    Am J Addict 11:151-60. 2002
    ..These studies did not reveal dysphoria to be a serious side effect produced by naltrexone treatment. Additional studies to evaluate long-term endocrine effects and antidepressant combination therapy are warranted...
  59. ncbi Methamphetamine: drug use and psychoses becomes a major public health issue in the Asia Pacific region
    Michael Farrell
    National Addiction Centre, 4 Windsor Walk, London SE5 8AF, UK
    Addiction 97:771-2. 2002
  60. doi Validation of the Alcohol, Smoking And Substance Involvement Screening Test (ASSIST)
    Rachel Humeniuk
    Drug and Alcohol, Services Council, Adelaide, Australia
    Addiction 103:1039-47. 2008
    ..The concurrent, construct and discriminative validity of the World Health Organization's Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) were examined in a multi-site international study...
  61. doi World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Substance Use and Related Disorders, Part 1: Alcoholism
    Michael Soyka
    Psychiatric Hospital Meiringen, Meiringen, Switzerland
    World J Biol Psychiatry 9:6-23. 2008
    ..This first part of the guidelines covers the treatment of alcohol dependence; Part 2 will be devoted to the treatment of drug dependence...
  62. ncbi Cynthia's Dilemma
    Walter Ling
    Integrated Substance Abuse Programs UCLA
    Am J Bioeth 2:55-6. 2002
  63. ncbi Substance use and treatment options in Cambodia
    Rachel Humeniuk
    WHO Collaborating Centre, Parkside, South Australia
    Drug Alcohol Rev 23:365-7. 2004
  64. ncbi Randomized controlled trials of the D1/D5 antagonist ecopipam for weight loss in obese subjects
    Arne Astrup
    Department of Human Nutrition, Faculty of Life Sciences, University of Copenhagen, 30 Rolighedsvej, 1958 Frederiksberg C, Denmark
    Obesity (Silver Spring) 15:1717-31. 2007
    ..To evaluate the efficacy and safety of the selective dopamine D1/D5 antagonist ecopipam for the treatment of obesity...
  65. ncbi The NIDA Methamphetamine Clinical Trials Group: a strategy to increase clinical trials research capacity
    Ahmed Elkashef
    Division of Treatment Research and Development, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
    Addiction 102:107-13. 2007
    ..This multi-site infrastructure would serve to run multiple Phases II and III protocols effectively and expeditiously...

Research Grants17

  1. Sustained-Release Methylphenidate For Management of Methamphetamine Use Disorders
    WALTER NMN LING; Fiscal Year: 2010
    ..A combination of treatment approaches may be most effective, and the proposed project will assess the utility of MPH in combination with proven behavioral therapy. ..
  2. Optimizing Outcomes Using Suboxone for Opiate Dependence
    Walter Ling; Fiscal Year: 2009
    ....
  3. Sustained-Release Methylphenidate For Management of Methamphetamine Use Disorders
    Walter Ling; Fiscal Year: 2009
    ..A combination of treatment approaches may be most effective, and the proposed project will assess the utility of MPH in combination with proven behavioral therapy. ..
  4. NATIONAL DRUG ABUSE TREATMENT CLINICAL TRIALS NETWORK
    Walter Ling; Fiscal Year: 2007
    ..abstract_text> ..
  5. NATIONAL DRUG ABUSE TREATMENT CLINICAL TRIALS NETWORK
    Walter Ling; Fiscal Year: 2007
    ....
  6. Optimizing Outcomes Using Suboxone for Opiate Dependence
    Walter Ling; Fiscal Year: 2007
    ....
  7. PAIN ANALGESIC RESPONSE IN OPIATE DEPENDENCE
    Walter Ling; Fiscal Year: 2003
    ..The results of this proposed study will help develop systematic guidelines for clinicians in the management of pain in opiate maintained individuals. ..
  8. Optimizing Outcomes Using Suboxone for Opiate Dependence
    WALTER NMN LING; Fiscal Year: 2010
    ....